Lucid-MS

This article has been disseminated on behalf of Quantum Biopharma Limited and may include a paid advertisement.

Headline, Quantum Biopharma Limited earns FDA clearance, Wall Street buy rating for lucid MS trial.

Multiple sclerosis drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost.

Nearly 1 million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control.

That gap has just gotten a serious new challenger.

Quantum Biopharma Limited has received FDA clearance to begin a Phase 2 trial of Lucid MS, a patented, first-in-class drug candidate aimed not at calming the immune system, but at protecting and potentially repairing the myelin sheath itself.

The clearance sets the stage for what would be the first time in history that a drug candidate built on this specific mechanism is tested in people living with the MS disease, a milestone significant enough that it has already drawn a fresh buy rating from Wall Street analysts.

This momentum places Quantum Biopharma solidly in a group of leading companies focused on the treatment of serious diseases and areas of significant unmet medical need across vaccines, ophthalmology, and neurological disease, including Sanofi, Roche Holding AG, Biogen Inc., and Clean Inc.